Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Orchid Pharma Ltd. Share Price
Day's Range
Low
₹809.05
High
₹880.25
Price Summary
| Previous Close | ₹817.30 |
|---|---|
| Day's Range | ₹809.05 - ₹880.25 |
| Open | ₹879.95 |
| 52 Week Range | ₹480.00 - ₹1,143.50 |
| Volume | 1,17,526 |
| Market Cap | ₹0.01 |
| Previous Close | ₹815.20 |
|---|---|
| Day's Range | ₹810.00 - ₹875.00 |
| Open | ₹875.00 |
| 52 Week Range | ₹471.30 - ₹1,142.65 |
| Volume | 6,382 |
| Market Cap | ₹0.01 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 960.54 |
|---|---|
| Market Cap (₹ in Mn) | 0.01 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 605.14 |
| TTM EPS (₹) | 1.45 |
| P/E Ratio | 73.48 |
| Book Value(₹) | 3.35 |
| PAT Margin (%) | 0.86 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 1.11 |
| Trade Value ( ₹ in Lacs) | 52.03 |
|---|---|
| Market Cap (₹ in Mn) | 0.01 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 605.14 |
| TTM EPS (₹) | 1.45 |
| P/E Ratio | 73.48 |
| Book Value(₹) | 3.35 |
| PAT Margin (%) | 0.86 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 1.11 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 2631.86 | 9219.26 |
| Expenses | N/A | N/A |
| PBT | -56.92 | 994.64 |
| Operating profit | 0.0 | 0.0 |
| Net profit | -56.92 | 996.57 |
About Orchid Pharma Ltd.
| Founded | 1992 |
|---|---|
| Managing Director | Manish Dhanuka |
| NSE Symbol | ORCHPHARMA |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,20,831.36 | 1,739.00 | 1,583.70 - 1,583.70 |
| Divi's Laboratories Ltd. | 2,42,074.16 | 8,880.00 | 5,647.50 - 5,647.50 |
| Torrent Pharmaceuticals Ltd. | 1,75,355.29 | 4,508.70 | 3,532.60 - 3,532.60 |
| Zydus Lifesciences Ltd. | 1,13,216.68 | 1,126.95 | 835.50 - 835.50 |
| Lenskart Solutions Ltd. | 1,10,289.40 | 618.70 | 0.00 - 0.00 |
| Apollo Hospitals Enterprise Ltd. | 1,09,132.55 | 7,580.00 | 6,696.50 - 6,696.50 |
| Laurus Labs Ltd. | 1,07,954.38 | 1,944.95 | 902.35 - 902.35 |
| Cipla Ltd. | 1,07,438.71 | 1,318.50 | 1,165.70 - 1,165.70 |
| Dr. Reddy's Laboratories Ltd. | 1,03,416.89 | 1,229.70 | 1,101.00 - 1,101.00 |
| Mankind Pharma Ltd. | 94,042.11 | 2,245.95 | 1,909.70 - 1,909.70 |
No Records Found
Latest News
Orchid Pharma informs about voting results and scrutinizer's report
In accordance with Regulation 44 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended, Orchid Pharma has informed that it enclosed Scrutinizer's Report including Voting Results for remote e-voting and e-voting at the 33rd Annual General Meeting of the Company held on Tuesday, September 29, 2026. The same are also available on the official website of the Company at https://www.orchidpharma.com/index.html.
The above information is a part of company’s filings submitted to BSE.
Park Medi World informs about disclosure
In continuation to its previous disclosure dated October 14, 2026, Park Medi World has informed that verification has been conducted by the Income Tax Department from October 12, 2026 to October 17, 2026, at some of the premises inter-alia related to the Company, some of its subsidiaries and officials. The details as required under the Listing Regulations read with SEBI circular HO/49/14/14(7)2025- CFD-POD2/I/3762/2026 dated January 30, 2026, are provided in ‘Annexure’ as enclosed. The disclosure is also being disseminated on the Company's website at https://www.parkhospital.in/.
The above information is a part of company’s filings submitted to BSE.
Cipla informs about updates
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Cipla has informed that an inspection was conducted by the United States Food and Drug Administration (USFDA) at the manufacturing facility of InvaGen Pharmaceuticals Inc. (InvaGen) (wholly owned subsidiary of the Company) located in Hauppauge, Long Island, New York, USA from 19th October, 2026 to 22nd October 2026 (ET). The Inspection was a routine current Good Manufacturing Practices (cGMP) Inspection. The inspection concluded with zero Form 483 observations.
The above information is a part of company’s filings submitted to BSE.
Beta Drugs - Quaterly Results
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202609 | 202509 | % Var | 202609 | 202509 | % Var | 202603 | 202503 | % Var | |
| Sales | 580.11 | 544.80 | 6.48 | 1138.37 | 1208.05 | -5.77 | 2254.30 | 2202.00 | 2.38 |
| Other Income | 18.59 | 27.43 | -32.23 | 37.26 | 57.18 | -34.84 | 111.43 | 61.92 | 79.96 |
| PBIDT | 82.52 | 74.78 | 10.35 | 202.75 | 179.61 | 12.88 | 396.87 | 376.08 | 5.53 |
| Interest | 6.51 | 29.74 | -78.11 | 22.52 | 57.62 | -60.92 | 118.07 | 47.56 | 148.25 |
| PBDT | 76.01 | 45.04 | 68.76 | 180.23 | 121.99 | 47.74 | 278.80 | 282.82 | -1.42 |
| Depreciation | 26.27 | 23.82 | 10.29 | 51.12 | 44.20 | 15.66 | 96.69 | 74.42 | 29.92 |
| PBT | 49.74 | 21.22 | 134.40 | 129.11 | 77.79 | 65.97 | 182.11 | 208.40 | -12.62 |
| TAX | 12.62 | 6.07 | 107.91 | 32.66 | 20.31 | 60.81 | 38.77 | 54.08 | -28.31 |
| Deferred Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PAT | 37.12 | 15.15 | 145.02 | 96.45 | 57.48 | 67.80 | 143.34 | 154.32 | -7.12 |
| Equity | 111.21 | 100.95 | 10.16 | 111.21 | 100.95 | 10.16 | 101.37 | 100.95 | 0.42 |
| PBIDTM(%) | 14.22 | 13.73 | 3.63 | 17.81 | 14.87 | 19.79 | 17.61 | 17.08 | 3.08 |
Lincoln Pharmaceuticals informs about board meeting
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Orchid Pharma Ltd. is ₹817.30 as of 2026-10-23.
The market capitalisation of Orchid Pharma Ltd. is ₹5,244.15 as of 2026-10-22.
The 1-year return of Orchid Pharma Ltd. is 87.55% as of 2026-10-23.
The P/E ratio of Orchid Pharma Ltd. is 73.48 as of 2026-10-23.
The 52-week high and low of Orchid Pharma Ltd. are ₹1,143.50 and ₹480.00, respectively, as of 2026-10-23.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
